LegoChem生物科學

2023年7月30日

朝鮮特色的開放式創新在國內獲得進展,外國製藥公司合作分享茉莉花崔×實驗室技術員測試物質與實驗室設備;藥物研發是一個資源密集型的過程。的趨勢不同大小的國內和外國企業之間的協作來實現成功的新藥物開發正在興起。業內人士認為這種合作的潛在模型“朝鮮式的開放創新”的製藥和生物技術行業。據業內人士7月30日,分析聯合治療的臨床試驗結果使用女士公司的非小細胞肺癌治療Leclaza和詹森的biospecific抗體治療Amivantamab預計將在今年下半年。女士介紹了Leclaza候選物質從國內生物技術公司Oscotec,優化出口前的物質和完成臨床試驗的技術全球製藥公司詹森。本例中是一個典型的例子作為合作公司或者大學發現一種新藥的候選人,國內製藥企業的發展,然後轉移到技術全球製藥巨頭。國內企業有創新能力開發新的候選物質或新技術,但他們往往缺乏必要的資金來完成開發過程。相比之下,國內大型製藥公司具有豐富的臨床經驗和資本引進新技術,但他們可能缺乏能力進行海外3期臨床試驗或海外安全許可證和業務操作。因此,成為轟動一時的新藥候選物質的可能性增加,當國內製藥公司收購風險物質,開發在某種程度上,然後技術轉移到全球製藥巨頭與海外臨床和市場營銷能力。 The industry views this kind of tripartite collaboration as gradually establishing itself as a Korean-style Open Innovation model. In particular, if this leads to overseas licensing and market release, ventures and pharmaceutical companies can generate significant revenue by receiving royalties based on sales, in addition to the existing milestone-based technical fee structure. The multinational pharmaceutical companies that hold the rights also stand to benefit. In a similar example, Yuhan Corporation is currently negotiating to transfer the technology for the allergy treatment GI-301, which it acquired from new drug development company GI Innovation, to a global pharmaceutical company. The company also imported degenerative disc treatment technology from Ensol Biosciences, developed it domestically, and exported the technology to Spine BioPharma in the U.S. in 2018. In addition, Handok transferred the technology of a target anticancer drug, jointly researched with CMG Pharmaceuticals, to a company in Singapore. Although the technology was returned, Bridge Biotherapeutics also introduced a candidate substance for idiopathic pulmonary fibrosis treatment from LegoChem Biosciences and exported the technology to Boehringer Ingelheim. However, the profits from such tripartite collaborations can be less than when one company develops a candidate substance from discovery to licensing. Still, industry insiders stress the importance of gathering funds and successful experiences through such collaborations, noting that there are not yet many companies in Korea capable of managing the full drug development process. POPULAR